CCL2 and cancer: Along with CCL7, which is downregulated 2-fold in our hPARG-expressing cells, CCL2 activates the CCR2 receptor (C-C Motif Chemokine Receptor Type 2) pathway, which expression in cancer cells have been demonstrated to promote immune suppression [89].